BERKELEY, Calif.--(BUSINESS WIRE)--ExThera Medical Corporation has joined a team led by Battelle that is developing a Dialysis-Like Therapeutics (DLT) device to treat sepsis. ExThera plans to work with Battelle and NxStage Medical (NXTM), Inc. on a contract from the Defense Advanced Research Projects Agency, or DARPA, to develop an innovative, new medical device.
ExThera is a pioneer in the development of broad-spectrum therapeutic devices to treat life-threatening bloodstream infections. As part of the DLT Program, Battelle will perform safety and efficacy studies on ExThera’s second-generation Seraph® Microbind® Affinity Blood Filter (Seraph).
“Each year there are 1.8 million new cases of bloodstream infection in the U.S. and Europe, causing patients serious complications and imposing a major cost burden on health care systems. With fewer anti-infective drugs being developed, and the continuing emergence of new drug-resistant pathogens, ExThera’s sorbent hemoperfusion device should become an important new tool for critical care clinicians.” Bob Ward, CEO, ExThera Medical.
Help employers find you! Check out all the jobs and post your resume.
